Xiconic Pharmaceuticals

Executive Summary

Xiconic Pharmaceuticals is a private biotechnology company developing novel antibody-drug conjugates (ADCs) for oncology, with a lead program, XCN-010, targeting activated matriptase (actM), a tumor-specific antigen. The company has generated compelling preclinical data demonstrating the potential of XCN-010 as a first-in-class therapeutic for a broad range of epithelial cancers and lymphomas. Xiconic is positioned to advance this candidate toward clinical development, leveraging its proprietary Matriptimab™-MMAE ADC platform. The company's focus on a validated target with high tumor specificity and a differentiated ADC approach supports its potential to address significant unmet needs in oncology.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for XCN-01070% success
• Q4 2026Initiation of Phase 1 Clinical Trial for XCN-01060% success
• Q2 2026Presentation of Updated Preclinical Data at Major Conference80% success